Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.

Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group.

J Infect Dis. 2009 Sep 1;200(5):687-97. doi: 10.1086/604731.

PMID:
19604043
2.

Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.

Bocket L, Yazdanpanah Y, Ajana F, Gerard Y, Viget N, Goffard A, Alcaraz I, Wattré P, Mouton Y.

J Antimicrob Chemother. 2004 Jan;53(1):89-94. Epub 2003 Nov 25.

PMID:
14645320
3.

Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.

Lafeuillade A, Poggi C, Hittinger G, Chadapaud S.

HIV Med. 2001 Oct;2(4):231-5.

4.

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.

Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD; EuroSIDA Study Group.

Antivir Ther. 2005;10(7):791-802.

PMID:
16312176
5.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
6.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R; COL40263 study.

J Antimicrob Chemother. 2010 Feb;65(2):307-15. doi: 10.1093/jac/dkp419. Epub 2009 Dec 15.

7.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
8.

Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.

Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):480-4. doi: 10.1097/QAI.0b013e3181bc478b.

PMID:
19801944
9.

The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients.

Gianotti N, Galli L, Boeri E, De Bona A, Guffanti M, Danise A, Salpietro S, Lazzarin A, Castagna A.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):447-52.

PMID:
16652052
10.

Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.

Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.

Pediatr Infect Dis J. 2006 Nov;25(11):1049-56.

PMID:
17072129
11.

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.

Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD; EuroSIDA in EuroCoord.

HIV Med. 2012 Jan;13(1):62-72. doi: 10.1111/j.1468-1293.2011.00943.x. Epub 2011 Aug 17.

12.

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):121-7.

PMID:
12394789
13.

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.

Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group.

AIDS. 2007 Mar 30;21(6):721-32.

PMID:
17413693
14.

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.

PMID:
17693883
15.

The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.

Maggiolo F, Ripamonti D, Torti C, Arici C, Antinori A, Quiros-Roldan E, Minoli L, Sighinolfi L, Nasta P, Suter F; MASTER Data Base Cohort.

Antivir Ther. 2006;11(7):923-9.

PMID:
17302255
16.

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.

Antivir Ther. 2009;14(3):339-47.

PMID:
19474468
17.

Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.

Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V.

Antivir Ther. 2001 Sep;6(3):179-83.

PMID:
11808752
18.

Impact of the number of failed therapeutic regimes on the development of resistance mutations to HIV-1 in northeast Brazil.

Medeiros MS, Arruda EA, Guerrant RL, Brown CC, Lima AA.

Braz J Infect Dis. 2007 Oct;11(5):451-5.

19.

[Clinical use of HIV-1 resistance genotyping. Predictive factors of poor virological evolution in salvage treatments].

Riera-Jaume M, Peñaranda-Vera M, Ribas-Blanco MA, Murillas-Angoiti J, Campins A, Salas-Aparicio A, Leyes-García M, Pareja-Bezares A, Pérez JL, Villalonga-Pieras C.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):225-31. Spanish.

PMID:
16725081
20.

Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.

Charpentier C, Laureillard D, Sodqi M, Si-Mohamed A, Karmochkine M, Bélec L, Weiss L, Piketty C.

J Clin Virol. 2008 Oct;43(2):212-5. doi: 10.1016/j.jcv.2008.07.001. Epub 2008 Aug 28.

PMID:
18760662

Supplemental Content

Support Center